Health Economics›Burkitt lymphoma›Untreated

Untreated

Burkitt lymphoma · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
BASIC N/A - intrathecal component	—	R 184 218	28d	—	—	~2	~R 236 953 indirect	—
R-CODOX-M/R-IVAC (Pegylated liposomal doxorubicin substituted) Variant #01	—	R 146 046	—	—	—	~2	~R 292 092 indirect	—
CALGB 10-002 regimen Variant #01	—	R 143 094	21d	—	—	~6	~R 249 655 indirect	—
R-CODOX-M/R-IVAC Variant #05	—	R 120 076	—	—	—	~2	~R 240 152 PFS proxy · indirect	1
R-Hyper-CVAD/R-MA Variant #01	—	R 115 130	—	—	—	~4	~R 253 282 indirect	—
GMALL-R N/A - protocol Partial	—	R 93 528	5d	—	—	~2	~R 186 783 indirect	—
R-CODOX-M (Pegylated liposomal doxorubicin substituted) Variant #01	—	R 69 269	—	—	—	~3	~R 207 808 indirect	—
R-COPADM Variant #01 Partial	—	R 53 356	21d	—	—	~2	~R 106 712 PFS proxy · indirect	1
DA-R-EPOCH Variant #01	—	R 28 060	21d	—	—	~8	~R 224 478 PFS proxy · indirect	1
R-CODOX-M Variant #01	—	R 27 669	28d	—	—	~3	~R 83 006 indirect	—
CODOX-M/IVAC Variant #02	—	R 18 220	—	—	—	~2	~R 36 439 indirect	—
CODOX-M Variant #02	—	R 1 911	—	—	—	~3	~R 5 732 indirect	—
COPAD Variant #01	—	R 1 674	—	—	—	~3	~R 5 023 indirect	—
COPADM Variant #01 Partial	—	R 1 546	—	—	—	~2	~R 3 093 indirect	—

14 of 14 regimens shown